Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ADVB · NASDAQ · Services-Medical Laboratories
Advanced Biomed (ADVB) · oqro.io/stocks/ADVB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.65−0.10 (−5.71%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Advanced Biomed is on record in SEC filings since 2006.
No open-market sale by an insider of Advanced Biomed (ADVB) was filed with the SEC in the last 90 days.
No trade in Advanced Biomed (ADVB) was disclosed by a member of Congress in the last 12 months.
Advanced Biomed's next results are expected on Feb 11, 2027. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−78.1% (−$5.90) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $7.55 on Nov 20, 2025 to $1.65 on Nov 20, 2026 (−78.1%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Services-Medical Laboratories company based in Reno, Nv.
Last 12 months
−78.2%
Market value
$2.73M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 11K shares sold short (0.7% of shares outstanding), +15.3% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2026
$128K
Year ended Jun 30, 2026
Net income, fiscal 2026
$6.68M
As reported in the annual filing
Shares outstanding
1.65M
As of Nov 12, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
No Schedule 13D or 13G filing on ADVB over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $214K, at Sep 30, 2026
Net income, last 12 months
$6.07M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Last results
—
Next results, expected
Feb 11, 2027
Purchases after results
Not enough history
From Advanced Biomed's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Advanced Biomed's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Latest annual report filed Oct 13, 2026. Read the filing
The risk factors section was largely rewritten: most of its 54 headings have no close match among the 82 of the year before, so no list of changes is shown.
We may from time to time be subject to legal and administrative proceedings and claims that arise in the ordinary course of business. We are not aware of any pending or threatened material legal or administrative proceedings against us. We do not believe that any claims exist where the outcome of such matters would have a material adverse effect on our consolidated financial position, operating results or cash flows. However, there can be no assurance such legal proceedings will not have a material impact on future results.
Source: SEC EDGAR, Form 10-K filed Oct 13, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 6,000 words.
We are a holding company incorporated in the State of Nevada. During the fiscal year ended June 30, 2026, the Company initiated a strategic corporate restructuring designed to transition its business focus from historical biotechnology activities to the artificial intelligence (“AI”) and financial algorithmic software sectors. Concurrently, following a reconfiguration of our Board of Directors and executive leadership, including the appointment of Mr. Xiaomin Chen as our Chief Executive Officer and Chairman of the Board, the Company executed a series of definitive agreements to orderly divest its medical and biotechnology operations.
And 18 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Oct 13, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 31.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (4.2% on ATS, 27.4% with other brokers), below its 26-week average of 56.6%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (34.2%), SIGMA X2 (14.9%), IBKR ATS (13.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Said its annual or quarterly report would be late
“The Registrant is unable to file its Form 10-K Annual Report for the period ended June 30, 2026, within the prescribed time period without unreasonable effort or expense, as the audit of its financial statements has not yet been completed. The Registrant anticipates that the Form 10-K Annual Report, together with the financial statements, will be filed within the prescribed extension period.”
NT 10-K on sec.govTop officer leaving
“Lu from his position as Chief Executive Officer, director and Chairman of the Board is neither a resignation by Mr.”
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K on sec.govSaid its annual or quarterly report would be late
“The Registrant is unable to file its Form 10-Q Quarterly Report for the period ended September 30, 2025, within the prescribed time period without unreasonable effort or expense, as the review of its financial statements has not yet been completed. The Registrant anticipates that the Form 10-Q Quarterly Report, together with the financial statements, will be filed within the prescribed extension period.”
NT 10-Q on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.